FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048169322> ?p ?o ?g. }

• W3048169322 endingPage "231.e1" @default.
• W3048169322 startingPage "219" @default.
• W3048169322 abstract "Background & AimsAldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with nonalcoholic steatohepatitis (NASH).MethodsWe performed a double-blind study of 78 patients with NASH at 9 centers in the United States. Key inclusion criteria were biopsy-proven NASH with Nonalcoholic Fatty Liver Disease Activity Score ≥4, stage 2 or 3 fibrosis by NASH Clinical Research Network classification, and absolute liver fat content ≥8%, measured by magnetic resonance imaging-proton density fat fraction. Patients were randomly assigned (1:2) to groups given subcutaneous placebo (n = 25) or aldafermin 1 mg (n = 53) daily for 24 weeks. The primary outcome was change in absolute liver fat content from baseline at week 24. Secondary outcomes included serum markers and histologic measures of fibrosis improvement and NASH resolution.ResultsAt week 24, the aldafermin group had a significant reduction in absolute liver fat content (reduction of 7.7%) compared with placebo (reduction of 2.7%; difference, reduction of 5.0%; 95% confidence interval, reduction of 8.0%−1.9%; P = .002). Aldafermin produced significantly greater decreases in levels of 7α-hydroxy-4-cholesten-3-one, bile acids, alanine and aspartate aminotransferases, and neoepitope-specific N-terminal pro-peptide of type III collagen (Pro-C3) than placebo. Fibrosis improvement (≥1 stage) with no worsening of NASH was achieved in 38% of patients receiving aldafermin vs 18% of patients receiving placebo (P = .10). NASH resolution with no worsening of fibrosis was observed in 24% of patients given aldafermin vs 9% of patients given placebo (P = .20). Discontinuations due to adverse events occurred in no patients in the aldafermin group and 4% of patients in the placebo group.ConclusionsIn a phase 2 trial of patients with NASH, aldafermin reduced liver fat and produced a trend toward fibrosis improvement. ClinicalTrials.gov, Number: NCT02443116. Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with nonalcoholic steatohepatitis (NASH). We performed a double-blind study of 78 patients with NASH at 9 centers in the United States. Key inclusion criteria were biopsy-proven NASH with Nonalcoholic Fatty Liver Disease Activity Score ≥4, stage 2 or 3 fibrosis by NASH Clinical Research Network classification, and absolute liver fat content ≥8%, measured by magnetic resonance imaging-proton density fat fraction. Patients were randomly assigned (1:2) to groups given subcutaneous placebo (n = 25) or aldafermin 1 mg (n = 53) daily for 24 weeks. The primary outcome was change in absolute liver fat content from baseline at week 24. Secondary outcomes included serum markers and histologic measures of fibrosis improvement and NASH resolution. At week 24, the aldafermin group had a significant reduction in absolute liver fat content (reduction of 7.7%) compared with placebo (reduction of 2.7%; difference, reduction of 5.0%; 95% confidence interval, reduction of 8.0%−1.9%; P = .002). Aldafermin produced significantly greater decreases in levels of 7α-hydroxy-4-cholesten-3-one, bile acids, alanine and aspartate aminotransferases, and neoepitope-specific N-terminal pro-peptide of type III collagen (Pro-C3) than placebo. Fibrosis improvement (≥1 stage) with no worsening of NASH was achieved in 38% of patients receiving aldafermin vs 18% of patients receiving placebo (P = .10). NASH resolution with no worsening of fibrosis was observed in 24% of patients given aldafermin vs 9% of patients given placebo (P = .20). Discontinuations due to adverse events occurred in no patients in the aldafermin group and 4% of patients in the placebo group. In a phase 2 trial of patients with NASH, aldafermin reduced liver fat and produced a trend toward fibrosis improvement. ClinicalTrials.gov, Number: NCT02443116." @default.
• W3048169322 created "2020-08-13" @default.
• W3048169322 creator A5017311913 @default.
• W3048169322 creator A5019006253 @default.
• W3048169322 creator A5028788314 @default.
• W3048169322 creator A5031884118 @default.
• W3048169322 creator A5038085416 @default.
• W3048169322 creator A5041247266 @default.
• W3048169322 creator A5048329422 @default.
• W3048169322 creator A5055923149 @default.
• W3048169322 creator A5058421287 @default.
• W3048169322 creator A5065016748 @default.
• W3048169322 creator A5069061894 @default.
• W3048169322 creator A5075081857 @default.
• W3048169322 creator A5075647936 @default.
• W3048169322 creator A5082999421 @default.
• W3048169322 creator A5083662534 @default.
• W3048169322 creator A5085710508 @default.
• W3048169322 creator A5086072427 @default.
• W3048169322 creator A5091625375 @default.
• W3048169322 date "2021-01-01" @default.
• W3048169322 modified "2023-10-15" @default.
• W3048169322 title "Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis" @default.
• W3048169322 cites W1555526329 @default.
• W3048169322 cites W1606178710 @default.
• W3048169322 cites W1964572117 @default.
• W3048169322 cites W2017511982 @default.
• W3048169322 cites W2062812115 @default.
• W3048169322 cites W2063437798 @default.
• W3048169322 cites W2086657341 @default.
• W3048169322 cites W2100193879 @default.
• W3048169322 cites W2132783496 @default.
• W3048169322 cites W2158378236 @default.
• W3048169322 cites W2166264058 @default.
• W3048169322 cites W2168741168 @default.
• W3048169322 cites W2214871873 @default.
• W3048169322 cites W2468692184 @default.
• W3048169322 cites W2580009538 @default.
• W3048169322 cites W2616559215 @default.
• W3048169322 cites W2625846788 @default.
• W3048169322 cites W2725385215 @default.
• W3048169322 cites W2744982526 @default.
• W3048169322 cites W2765324118 @default.
• W3048169322 cites W2770129291 @default.
• W3048169322 cites W2793275191 @default.
• W3048169322 cites W2793543636 @default.
• W3048169322 cites W2808779488 @default.
• W3048169322 cites W2821544409 @default.
• W3048169322 cites W2889932786 @default.
• W3048169322 cites W2904469476 @default.
• W3048169322 cites W2905340379 @default.
• W3048169322 cites W2918007312 @default.
• W3048169322 cites W2921756348 @default.
• W3048169322 cites W2985579744 @default.
• W3048169322 cites W2986883158 @default.
• W3048169322 cites W2993083975 @default.
• W3048169322 cites W2994629683 @default.
• W3048169322 cites W2998643329 @default.
• W3048169322 cites W3003361050 @default.
• W3048169322 cites W3009945933 @default.
• W3048169322 cites W3012883032 @default.
• W3048169322 cites W3129818723 @default.
• W3048169322 cites W3183857127 @default.
• W3048169322 doi "https://doi.org/10.1053/j.gastro.2020.08.004" @default.
• W3048169322 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32781086" @default.
• W3048169322 hasPublicationYear "2021" @default.
• W3048169322 type Work @default.
• W3048169322 sameAs 3048169322 @default.
• W3048169322 citedByCount "143" @default.
• W3048169322 countsByYear W30481693222020 @default.
• W3048169322 countsByYear W30481693222021 @default.
• W3048169322 countsByYear W30481693222022 @default.
• W3048169322 countsByYear W30481693222023 @default.
• W3048169322 crossrefType "journal-article" @default.
• W3048169322 hasAuthorship W3048169322A5017311913 @default.
• W3048169322 hasAuthorship W3048169322A5019006253 @default.
• W3048169322 hasAuthorship W3048169322A5028788314 @default.
• W3048169322 hasAuthorship W3048169322A5031884118 @default.
• W3048169322 hasAuthorship W3048169322A5038085416 @default.
• W3048169322 hasAuthorship W3048169322A5041247266 @default.
• W3048169322 hasAuthorship W3048169322A5048329422 @default.
• W3048169322 hasAuthorship W3048169322A5055923149 @default.
• W3048169322 hasAuthorship W3048169322A5058421287 @default.
• W3048169322 hasAuthorship W3048169322A5065016748 @default.
• W3048169322 hasAuthorship W3048169322A5069061894 @default.
• W3048169322 hasAuthorship W3048169322A5075081857 @default.
• W3048169322 hasAuthorship W3048169322A5075647936 @default.
• W3048169322 hasAuthorship W3048169322A5082999421 @default.
• W3048169322 hasAuthorship W3048169322A5083662534 @default.
• W3048169322 hasAuthorship W3048169322A5085710508 @default.
• W3048169322 hasAuthorship W3048169322A5086072427 @default.
• W3048169322 hasAuthorship W3048169322A5091625375 @default.
• W3048169322 hasBestOaLocation W30481693221 @default.
• W3048169322 hasConcept C126322002 @default.
• W3048169322 hasConcept C134018914 @default.
• W3048169322 hasConcept C142724271 @default.
• W3048169322 hasConcept C203092338 @default.
• W3048169322 hasConcept C204787440 @default.

• next